Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Prostatic Neoplasms × Estramustine × Clear all

Phase

Status

Sponsor Class

OTHER 23 NIH 8 NETWORK 7 INDUSTRY 1 FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Prednisone 83 Docetaxel 64 enzalutamide 59 Abiraterone Acetate 55 Leuprolide 43 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 41 abiraterone 27 apalutamide 25 bicalutamide 22 pembrolizumab 20 Zoledronic Acid 20 Prednisolone 20 radium Ra 223 dichloride 19 Goserelin 19 darolutamide 18 Triptorelin Pamoate 13 sipuleucel-T 12 luprolide acetate gel depot 12 cabazitaxel 12 Androgen Antagonists 12 Dexamethasone 11 olaparib 10 Injections 10 gallium 68 PSMA-11 9 Pluvicto 9 Ipilimumab 9 Mitoxantrone 8 orteronel 7 Standard of Care 7 Lutetium-177 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00705822 2010-11-30

PROSTATA

Sanofi

Phase 3 Terminated

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡